Correction: miR146a-mediated targeting of FANCM during inflammation compromises genome integrity.

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
26 May 2020
Historique:
entrez: 12 6 2020
pubmed: 12 6 2020
medline: 12 6 2020
Statut: epublish

Résumé

[This corrects the article DOI: 10.18632/oncotarget.10275.].

Identifiants

DOI: 10.18632/oncotarget.27481 PMID: 32523656 PMC: PMC7260119
pubmed: 32523656
doi: 10.18632/oncotarget.27481
pii: 27481
pmc: PMC7260119
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

2024-2025

Commentaires et corrections

Type : ErratumFor

Informations de copyright

Copyright: © 2020 Sundaravinayagam et al.

Auteurs

Devakumar Sundaravinayagam (D)

Laboratory of Genomic Instability and Cancer Therapeutics, Cancer Mutation Research Center, Chosun University School of Medicine, Gwangju, Republic of Korea.
Department of Pharmacology, Chosun University School of Medicine, Gwangju, Republic of Korea.

Hye Rim Kim (HR)

Laboratory of Genomic Instability and Cancer Therapeutics, Cancer Mutation Research Center, Chosun University School of Medicine, Gwangju, Republic of Korea.
Department of Cellular and Molecular Medicine, Chosun University School of Medicine, Gwangju, Republic of Korea.

TingTing Wu (T)

Laboratory of Genomic Instability and Cancer Therapeutics, Cancer Mutation Research Center, Chosun University School of Medicine, Gwangju, Republic of Korea.
Department of Cellular and Molecular Medicine, Chosun University School of Medicine, Gwangju, Republic of Korea.

Hyun Hee Kim (HH)

Laboratory of Genomic Instability and Cancer Therapeutics, Cancer Mutation Research Center, Chosun University School of Medicine, Gwangju, Republic of Korea.
Department of Cellular and Molecular Medicine, Chosun University School of Medicine, Gwangju, Republic of Korea.

Hyun-Seo Lee (HS)

Laboratory of Genomic Instability and Cancer Therapeutics, Cancer Mutation Research Center, Chosun University School of Medicine, Gwangju, Republic of Korea.
Department of Pharmacology, Chosun University School of Medicine, Gwangju, Republic of Korea.

Semo Jun (S)

Laboratory of Genomic Instability and Cancer Therapeutics, Cancer Mutation Research Center, Chosun University School of Medicine, Gwangju, Republic of Korea.
Department of Pharmacology, Chosun University School of Medicine, Gwangju, Republic of Korea.

Jeong-Heon Cha (JH)

Department of Oral Biology, Department of Applied Life Science, The Graduate School, Yonsei University College of Dentistry, Seoul, Republic of Korea.

Younghoon Kee (Y)

Department of Cell Biology, Microbiology, and Molecular Biology, College of Arts and Sciences, University of South Florida, Tampa, Florida, United States of America.

Ho Jin You (HJ)

Laboratory of Genomic Instability and Cancer Therapeutics, Cancer Mutation Research Center, Chosun University School of Medicine, Gwangju, Republic of Korea.
Department of Pharmacology, Chosun University School of Medicine, Gwangju, Republic of Korea.

Jung-Hee Lee (JH)

Laboratory of Genomic Instability and Cancer Therapeutics, Cancer Mutation Research Center, Chosun University School of Medicine, Gwangju, Republic of Korea.
Department of Cellular and Molecular Medicine, Chosun University School of Medicine, Gwangju, Republic of Korea.

Classifications MeSH